IPI-504

The heat shock chaperone protein (HSP-90) has emerged as a promising target for cancer therapy. Infinity Pharmaceuticals’ IPI-504 is one of many experimental heat shock protein inhibitors vying for a spot in the cancer market. [...]

Infinity's IPI-504 completes phase I HSP90 inhibitor IPI-504 from Infinity has completed phase I testing at five sites in the United States and Canada. HSP-90 is a protein that acts as a chaperone for other [...]